Release Date: November 8, 2013
Last Reviewed: October 8, 2013
Expiration Date: November 7, 2014
Time to Complete Activity: 1.0 hours
*This activity expired for credit on November 7, 2014 and is no longer available for credit
 This activity is sponsored by Global Education Group.
 Paradigm Medical Communications, LLC is the educational partner.
This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit
The educational design of this activity addresses the needs of urologists and other healthcare providers interested in the management of patients with urologic conditions and men’s health issues.
The diagnosis of hypogonadism is controversial, with conflicting definitions of normal versus low testosterone levels existing across various agencies and research groups. Nevertheless, enough evidence of the negative impact of low testosterone on male health has accumulated to make the condition a growing concern for clinicians. The condition is associated with symptoms including erectile dysfunction, loss of libido, and decreased energy levels, as well as comorbidities including obesity, decreased muscle mass, and potential cardiovascular complications, and can result in decreased vitality and a reduced quality of life. However, studies have shown that a significant proportion of men with hypogonadism go undiagnosed, or do not receive testosterone replacement therapy due to either poor physician understanding of the benefits and safety of therapy or physicians’ concerns of exacerbating other comorbid conditions. Urologists and other healthcare providers need an awareness of the various conflicting definitions of hypogonadism, screening guidelines, and the clinical data supporting the benefits and relative safety of testosterone replacement therapy.
After completing this activity, the participant should be better able to:
  • Describe the relationship of male hypogonadism with comorbid chronic illnesses and the associated impact on patient morbidity and mortality.
  • Explain an appropriate evidence-based diagnostic approach after recognizing the signs and symptoms of male hypogonadism.
  • Integrate currently approved evidence-based therapies for male hypogonadism as part of comprehensive treatment for common comorbid conditions to improve patient outcomes.
Culley C. Carson III, MD
Rhodes Distinguished Professor and Chief of Urology
John Sloan Rhodes and John Flint Rhodes Distinguished Professor
Division of Urology
University of North Carolina at Chapel Hill
Chapel Hill, NC
Mohit Khera, MD, MBA, MPH
Assistant Professor of Urology
Scott Department of Urology
Baylor College of Medicine
Director, Laboratory for Andrology Research
McNair Medical Institute
Houston, TX
  • Introduction
  • Prevalence of TD
  • TRT Controversies
  • Diagnosis of Male Hypogonadism
  • Testosterone Treatment Options
  • Benefits of TRT
  • Conclusion
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive a CME certificate of participation, the participant should:
  • Follow instructions to register or log in with your professional information and complete the pretest.
  • View the online activity in its entirety.
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the activity.
  • A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
There is no fee required for participation in this activity.
Supported Browsers
Internet Explorer 7+, Firefox 4+, Safari 3+, Chrome 1+, Opera 9+
Technical Support
If you have any technical problems, please call (845) 398-5938 or email
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Reported Financial Relationship
Culley C. Carson III, MD, FACS
Advisory Board: Lilly USA, LLC
Consultant: Auxilium Pharmaceuticals, AMS, Coloplast
Grant/Research Support: Auxilium Pharmaceuticals
Honoraria: Auxilium Pharmaceuticals, AMS, Coloplast
Speaker's Bureau: Auxilium Pharmaceuticals, AMS, Coloplast, GlaxoSmithKline, Lilly USA, LLC
Mohit Khera, MD
Consultant: Auxilium Pharmaceuticals, Meda Pharmaceuticals, Merck, Slate Pharmaceuticals
Grant/Research Support: Allergan
Speaker’s Bureau: Auxilium Pharmaceuticals, Lilly USA, LLC
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager
Reported Financial Relationship
Ashley Marostica, RN, MSN
Nothing to disclose
Amanda Glazar, PhD
Nothing to disclose
Paradigm Medical Communications, LLC staff members have no financial conflicts to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Paradigm do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.­­­­
If you have any questions or comments regarding this policy, please email: